Entities / Company
AxoGen.
company
- Reports this week
- 0
- Active events
- 0
- Connections
- 29
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.Some support2 reports
-
AxoGen stock is currently traded on the Nasdaq exchange.Some support1 report
-
AxoGen and Harris researched tissue regeneration with colleagues on August 11, 2026.Some support1 report
-
Michael Dale was named CEO of AxoGen, a company with operations in Tampa, Florida.Some support6 reports
-
AxoGen provided a strategic investment to Trace Biosciences on July 29, 2026.Some support1 report
Gone quiet
No new reports in 90+ days-
AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application.Some support5 reports1 development inside
-
AxoGen, a Florida-based company, announced on July 3rd that it invested in Avance and presented at a Goldman Sachs conference.Speculative1 report
-
Zacks Earnings ESP provided insight into business conditions for AxoGen on July 29, 2025.Some support1 report
-
AxoGen operates within the medical instruments industry, and Zacks Rank harnesses earnings estimate revisions for stock analysis.Some support1 report
-
Automated Insights generated a story on August 5, 2025, involving the company AxoGen.Some support1 report
-
First Light Asset Management is reported as the largest shareholder of AxoGen.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around AxoGen this week
News at the entities that move AxoGen most-
FDA StructuralFDA conducted surprise raids and inspections in Bihar state, directed by state government officials.Moves AxoGen
-
Nasdaq StructuralVMware's stock performance was tracked on the Nasdaq exchange on October 25, 2026.Moves AxoGen
-
Citigroup OperationalRoyal Bank of Canada dropped its price objective for Crown Castle Inc., while Citigroup reiterated an outperform rating.Moves AxoGen
-
Harris OperationalPolitical analysts and market observers are updating odds for the Georgia Senate race, driven by Donald Trump's actions.Moves AxoGen
-
Raymond James Financial Mentioned togetherRaymond James Financial reaffirmed its outperformance rating for Amazon.com, Inc. on October 25, 2026.Moves AxoGen
-
Tampa Shared contextCarlos Duque served as the primary representative for an innovation center in Tampa.Moves AxoGen
Connections
The 9 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
The FDA formally regulates AxoGen's product development, managing the BLA filing and clearance process for its medical devices.
-
Michael Dale Structural
Michael Dale holds the role of CEO and Director of AxoGen.
-
Nasdaq Structural
AxoGen is a company that trades on the Nasdaq stock exchange.
-
Tampa Shared context
AxoGen is based and operates within the geographical context of Tampa, Florida.
-
Citigroup Operational
Citigroup provides financial ratings and analysis on AxoGen's shares.
-
Harris Operational
The relationship is implied to be a collaborative research partnership focused on tissue regeneration.
-
Raymond James Financial Mentioned together
Raymond James Financial provided a price objective analysis for AxoGen.
-
Bank of America Mentioned together
Bank of America began providing investment coverage for AxoGen shares.
Show all 9 connections
-
Alachua Shared context
AxoGen operates from an office located in Alachua, Florida.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
2 eventsShow 1 earlier month
June 2026
8 events- The FDA has issued a Major Amendment regarding AxoGen's submission on August 25, 2025.
- Michael Dale was named CEO of AxoGen, a company with operations in Tampa, Florida.
- AxoGen is seeking BLA approval for its Avance Nerve Graft, and the FDA extended the review date for the application.
- AxoGen, a Florida-based company, announced on July 3rd that it invested in Avance and presented at a Goldman Sachs conference.
- Zacks Earnings ESP provided insight into business conditions for AxoGen on July 29, 2025.
- AxoGen operates within the medical instruments industry, and Zacks Rank harnesses earnings estimate revisions for stock analysis.
- Automated Insights generated a story on August 5, 2025, involving the company AxoGen.
- First Light Asset Management is reported as the largest shareholder of AxoGen.